1009298-09-2 | AZD8055

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$14.00	$10.00
10mg	98%	in stock	$45.00	$32.00
100mg	98%	in stock	$405.00	$284.00
200mg	≥99%	in stock	$775.00	$542.00
1g	98%	in stock	$1,458.00	$1,020.00

Description

• Catalog Number: AA03979
• Chemical Name: AZD8055
• CAS Number: 1009298-09-2
• Molecular Formula: C25H31N5O4
• Molecular Weight: 465.5447
• MDL Number: MFCD16660191
• SMILES: OCc1cc(ccc1OC)c1ccc2c(n1)nc(nc2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C

Computed Properties

• Complexity: 659
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 34
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 5
• XLogP3: 2.6

Literature

• Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.

  Molecular oncology 20140501

• mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection.

  Virology 20140301

• PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20130801

• Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

  Bioorganic & medicinal chemistry letters 20130301

• Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.

  British journal of cancer 20120925

• The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

  Leukemia 20120601

• Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis.

  The Biochemical journal 20120515

• TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO.

  Cell metabolism 20120502

• Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).

  Cancer research 20120401

• Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines.

  Experimental neurology 20120201

• Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

  PloS one 20120101

• Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1.

  The Journal of biological chemistry 20111118

• Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.

  Cancer research 20110801

• mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

  Cancer discovery 20110617

• mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.

  Cancer research 20110615

• Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.

  Biochemical Society transactions 20110401

• Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice.

  British journal of cancer 20110329

• Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.

  Journal of medicinal chemistry 20110310

• Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.

  Bioorganic & medicinal chemistry letters 20100801

• Mammalian autophagy: core molecular machinery and signaling regulation.

  Current opinion in cell biology 20100401

• AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

  Cancer research 20100101

• Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

  Nature 20090716

• Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

  Current biology : CB 20040727

• Regulation of longevity and stress resistance by Sch9 in yeast.

  Science (New York, N.Y.) 20010413